Radiosynthesis and biodistribution of a histamine H3 receptor antagonist 4-[3-(4-piperidin-1-yl-but-1-ynyl)-[11C]benzyl]-morpholine: evaluation of a potential PET ligand

Nuclear Medicine and Biology

Volumn 33, Issue 6, 2006, Pages 801-810

  Airaksinen, Anu J ^a   Jablonowski, Jill A ^b   van der Mey, Margreet ^a   Barbier, Ann J ^b   Klok, Rob P ^a   Verbeek, Joost ^a   Schuit, Robert ^a   Herscheid, Jacobus D M ^a   Leysen, Josee E ^a   Carruthers, Nicholas I ^b   Lammertsma, Adriaan A ^a   Windhorst, Albert D ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Antagonist; Autoradiography; Biodistribution; Brain; Histamine H3 receptor; PET ligand

Indexed keywords

4 [3 (4 PIPERIDIN 1 YLBUT 1 YNYL)BENZYL]MORPHOLINE; 4 [3 (4 PIPERIDIN 1 YLBUT 1 YNYL)BENZYL]MORPHOLINE C 11; ANTIHISTAMINIC AGENT; CARBON 11; DRUG METABOLITE; HISTAMINE; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR ANTAGONIST; JNJ 10181457; JNJ 5207852; RADIOLIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN CORTEX; BRAIN REGION; BRAIN SLICE; CHEMICAL REACTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG UPTAKE; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; OLFACTORY BULB; PLASMA PROTEIN BINDING; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; RAT;

ANIMALS; AUTORADIOGRAPHY; BRAIN; CARBON RADIOISOTOPES; HISTAMINE ANTAGONISTS; LIGANDS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MORPHOLINES; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RECEPTORS, HISTAMINE H3; TISSUE DISTRIBUTION;

EID: 33747352284     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2006.05.008     Document Type: Article

References (46)

1. 3) of histamine receptor. Nature 302 (1983) 832-837
2. 3-receptors. Nature 327 (1987) 117-123
3. Brown R.E., Stevens D.R., and Haas H.L. The physiology of brain histamine. Prog Neurobiol 63 (2001) 637-672
4. 3 autoreceptors modulate histamine synthesis through calcium/calmodulin- and cAMP-dependent protein kinase pathways. Mol Pharmacol 67 (2005) 195-203
5. 3 receptors. J Neural Transm Gen Sect 93 (1993) 1-10
6. 3 receptor-mediated inhibition of serotonin release in the rat brain cortex. Naunyn Schmiedebergs Arch Pharmacol 337 (1988) 588-590
7. 3 receptors. Naunyn Schmiedebergs Arch Pharmacol 340 (1989) 633-638
8. 3-receptor-induced attenuation of norepinephrine exocytosis: a decreased protein kinase activity mediates a reduction in intracellular calcium. J Pharmacol Exp Ther 312 (2005) 272-280
9. 3 receptor-mediated depression of synaptic transmission in the dentate gyrus of the rat in vitro. J Physiol 496 (1996) 175-184
10. 3H]GABA release from depolarization-stimulated slices of rat substantia nigra pars reticulata. Neuroscience 80 (1997) 241-249
11. 3 receptors regulating acetylcholine release in rat entorhinal cortex. Br J Pharmacol 114 (1995) 1518-1522
12. 3 receptors in rat brain areas. Neuroscience 52 (1993) 169-189
13. 125I]iodophenpropit. Naunyn Schmiedebergs Arch Pharmacol 362 (2000) 60-67
14. Pillot C., Heron A., Cochois V., Tardivel-Lacombe J., Ligneau X., Schwartz J.-C., et al. A detailed mapping of the histamine H(3) receptor and its gene transcripts in rat brain. Neuroscience 114 (2002) 173-193
15. 3 receptor. Mol Pharmacol 55 (1999) 1101-1107
16. 3 receptor isoforms with different brain expression and signaling properties. Mol Pharmacol 59 (2001) 1-8
17. Wellendorph P., Goodman M.W., Burstein E.S., Nash N.R., Brann M.R., and Weiner D.M. Molecular cloning and pharmacology of functionally distinct isoforms of the human histamine H(3) receptor. Neuropharmacology 42 (2002) 929-940
18. 3 receptor: evidence for two isoforms. Neuroreport 11 (2000) 755-759
19. 3 receptor heterogeneity. Life Sci 73 (2003) 3043-3072
20. 3 receptors. Bioorg Med Chem Lett 11 (2001) 951-954
21. 3H]Nα-methylhistamine binding differ from that of rodents. Eur J Pharmacol 377 (1999) 233-239
22. 3 receptor agonists and antagonists. Trends Pharmacol Sci 19 (1998) 177-183
23. -/- mice. Eur J Neurosci 19 (2004) 1992-1996
24. 3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization. J Pharmacol Exp Ther 305 (2003) 897-908
25. 3 antagonist. Br J Pharmacol 143 (2004) 649-661
26. 3 receptor antagonist. Eur J Pharmacol 487 (2004) 183-197
27. 3 receptor blockade by thioperamide enhances cognition in rats without inducing locomotor sensitization. Psychopharmacology 167 (2003) 363-372
28. 3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 25 (2004) 618-625
29. Tai Y.F., and Piccini P. Applications of positron emission tomography (PET) in neurology. J Neurol Neurosurg Psychiatry 75 (2004) 669-676
30. Gatley J.S., Volkow N.D., Fowler J.S., Ding Y.-S., Logan J., Wang G.-J., et al. Positron emission tomography and its use to image the occupancy of drug binding sites. Drug Dev Res 59 (2003) 194-207
31. Eckelman W.C. The use of PET and knockout mice in the drug discovery process. Drug Discov Today 8 (2003) 404-409
32. Elsinga P.H. Radiopharmaceutical chemistry for positron emission tomography. Methods 27 (2002) 208-217
33. van Waarde A. Measuring receptor occupancy with PET. Curr Pharm Des 6 (2000) 1593-1610
34. 3-receptor antagonists and potential PET/SPECT ligands. Arch Pharm Pharm Med Chem 334 (2001) 45-52
35. 3 receptor. Bioorg Med Chem 7 (1999) 1761-1767
36. 4 receptor ligands. Exp Opin Ther Patents 13 (2003) 851-865
37. 3 receptor drugs. Nat Rev Drug Discov 4 (2005) 107-120
38. 3 receptor ligands. International Applied Publication No. WO 2005097778, October 20, 2005.
39. Halldin C., and Högberg T. Radiotracers: synthesis and use in imaging. In: Krogsgaard-Larsen P., Liljefors T., and Madsen U. (Eds). A textbook of drug design and development. 3rd ed. (2002), Taylor and Francis, London 217-222
40. 11C]verapamil for measuring P-glycoprotein function with positron emission tomography. J Label Compd Radiopharm 45 (2002) 1199-1207
41. 3 receptor ligands: 4-(aminoalkoxy)-benzylamines. J Med Chem 46 (2003) 3938-3944
42. Apodaca R, Deng X, Jablonowski JA, Mani N, Pandit CR, Xiao W, Preparation of substituted phenylalkynes as H3 receptor ligands. US Patent Appl Publ No. US 2004002604, January 1, 2004.
43. Apodaca R, Xiao W, Jablonoski JA, Preparation of substituted phenylalkynes for use in histamine-mediated disorders. International Applied Publication No. WO 2003050099, June 19, 2003.
44. Toyota H., Dugovic C., Koehl M., Laposky A.D., Weber C., Ngo K., et al. Behavioral characterization of mice lacking histamine H(3) receptors. Mol Pharmacol 62 (2002) 389-397
45. van der Mey M., Janssen C.G.M., Janssens F.E., Jurzak M., Langlois X., Sommen F.M., et al. Synthesis and biodistribution of [(11)C]R116301, a promising PET ligand for central NK(1) receptors. Bioorg Med Chem 13 (2005) 1579-1586
46. Quevedo M.A., Moroni G.N., and Briñón M.C. Human serum albumin binding of novel antiretroviral nucleoside derivatives of AZT. Biochem Biophys Res Com 288 (2001) 954-960